Skip to main content
TipRanks
Go Ultimate75% OFF

Synlogic (SYBX) AI Stock Analysis

558 Followers
SYBX

Synlogic

(Other OTC:SYBX)

Select Model
Rating:60Neutral
Price Target:$1.00▼(-6.98% Downside)
Action:reiterated
Date:08/18/26

The overall score of 60 is heavily supported by the transformative merger announcement with Caldera Therapeutics and strong bullish price momentum. However, this is largely offset by severe fundamental weaknesses, including a complete lack of revenue, significant asset shrinkage, and negative earnings.

Positive Factors
Debt-Free Balance SheetDebt falling to zero materially reduces fixed financial obligations and refinancing exposure, while positive equity provides a cushion for continued development. This improves financial flexibility and lowers balance-sheet risk, although it does not by itself establish operating self-sufficiency.
Negative Factors
No Commercial RevenueThe absence of recurring commercial revenue leaves Synlogic dependent on partnerships, financing, or other external sources to fund development. It also limits earnings visibility and operating leverage, making future performance highly dependent on successful clinical progress.

Synlogic (SYBX) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%SYBX-34.85%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$12.74M
Dividend Yield
―
Average Volume (3M)
19.50K
Price to Earnings (P/E)
-6.0
Beta (1Y)
0.71
Revenue Growth
―
EPS Growth
35.21%
Country
US
Employees
1
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Synlogic Business Overview & Revenue Model

Company Description

Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.

How the Company Makes Money

Synlogic has historically generated revenue primarily through collaboration and partnership arrangements rather than product sales, as it has been a clinical-stage company without marketed, approved therapeutics. Under such arrangements, revenue is t...

Synlogic Financial Statement Overview

Summary

Scores very low due to zero revenue generation, massive reductions in total assets, and persistent negative cash flows, although the lack of debt removes immediate insolvency risk.

Income Statement

10Very Negative

Balance Sheet

45Neutral

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue008,0003.37M1.18M1.75M
Gross Profit008,0003.37M1.18M1.75M
EBITDA-5.27M-3.53M-23.01M-55.31M-63.63M-58.12M
Net Income-2.23M-1.00M-23.36M-57.28M-66.15M-60.56M
Balance Sheet
Total Assets11.85M15.45M19.83M75.55M110.86M174.74M
Cash, Cash Equivalents and Short-Term Investments11.56M14.67M18.86M47.75M77.63M128.59M
Total Debt00017.27M20.30M20.59M
Total Liabilities1.67M3.58M7.08M32.90M28.25M27.47M
Stockholders Equity10.18M11.86M12.75M42.66M82.61M147.27M
Cash Flow
Free Cash Flow-4.03M-4.36M-31.67M-51.83M-57.62M-52.88M
Operating Cash Flow-4.03M-4.36M-31.66M-51.61M-56.89M-52.20M
Investing Cash Flow0167.00K25.34M38.77M58.35M-53.25M
Financing Cash Flow1,0000172.00K20.94M-2.04M89.38M

Synlogic Technical Analysis

Technical Analysis SentimentPositive
Last Price1.07

Price Trends

50DMA1.09Negative
100DMA1.03Positive
200DMA0.84Positive

Market Momentum

MACD-0.01Negative
RSI53.59Neutral
STOCH82.35Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYBX, the sentiment is Positive. The current price of 1.07 is above the 20-day moving average (MA) of 1.03, below the 50-day MA of 1.09, and above the 200-day MA of 0.84, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 53.59 is Neutral, neither overbought nor oversold. The STOCH value of 82.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYBX.

Synlogic Risk Analysis

Synlogic disclosed 34 risk factors in its most recent earnings report. Synlogic reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.1A. Risk FactorsQ1, 2026
2.As a result of our delisting from Nasdaq, we are more likely to require holders of our warrants who exercise their warrants to do so on a cashless basis and such holders may receive fewer shares of common stock upon exercise than they would have received had they been able to pay the exercise price of their warrants in cash.Q4, 2025
3.Our securityholders may face restrictions on the resale of our securities due to state "blue sky" laws.Q4, 2025

Synlogic Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SYBX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SYBXSYBX60Neutral$13.17M-5.99-19.10%――35.21%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
LSTALSTA49Neutral$13.07M-0.64-164.72%―-90.65%11.37%
ICUICU48Neutral$4.46M-0.23-261.10%―145.74%75.46%
ALLRALLR44Neutral$15.18M-0.97-349.08%――38.64%
APVOAPVO41Neutral$1.08M-0.00-201.49%――99.41%
CINGCING40Underperform$62.53M-1.03-149.01%――47.13%

* Healthcare Sector Average

Performance Comparison

-100%0%100%200%SYBXLSTAAPVOICUCINGALLRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SYBX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SYBXSynlogic Inc1.07-0.61-36.39%
LSTALisata Therapeutics, Inc.1.21-0.88-42.11%
APVOAptevo0.59-24.07-97.59%
ICUSeastar Medical Holding Corporation0.84-2.19-72.35%
CINGCingulate, Inc.4.300.9729.13%
ALLRAllarity Therapeutics, Inc.0.95-0.17-14.91%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 18, 2026